Perspectum and HepQuant Announce Partnership to Provide Fuller Picture of Liver Health | Business
SAN FRANCISCO & DENVER – (BUSINESS WIRE) – November 1, 2021–
Perspectum and HepQuant are proud to announce a strategic business partnership to provide seamless delivery of HepQuant’s liver function assessment technology through Perspectum’s Contract Research Organization (CRO) services.
This press release features multimedia. See the full version here: https://www.businesswire.com/news/home/20211101005151/en/
The collaboration will allow pharmaceutical companies sponsoring clinical trials in liver disease, including cirrhosis of the liver, non-alcoholic steatohepatitis (NASH), autoimmune liver disease and liver cancer, to benefit from expertise in imaging and functional testing from Perspectum’s Pharma Solutions. A combined functional analysis and imaging platform could provide the next generation assessment needed to get a complete picture of liver health.
“We are delighted to collaborate with HepQuant,” said Dr Rajarshi Banerjee, CEO of Perspectum. “We have witnessed the unmet need for liver function testing and recognize HepQuant as a leader in the non-invasive functional assessment of the liver. Along with our premier quantitative imaging platform, we believe that collaborating to improve the way we diagnose, treat and monitor chronic liver disease, cirrhosis and liver cancer will best serve the large and growing number. of people suffering from these diseases. “
The partnership will also include the study of the clinical utility of the combination of functional and imaging modalities in potential clinical pathways for the future diagnosis and treatment of liver disease. A comprehensive picture of liver health could be helpful to payers making decisions about coverage for current and future treatments, especially fatty liver and fibrotic disease.
“HepQuant believes that combinations of new non-invasive testing platforms could improve the safety and reliability of patient assessment with liver disease,” said Dr. Gregory T. Everson, Founder and CEO of HepQuant. “Function is a key part of this overall assessment. This functional assessment coupled with Perspectum’s Liver Multi-scan provides a comprehensive picture of liver health with the goal of improving patient management, both in clinical trials and in the clinic.
Perspectum, a global medical technology company with offices in the UK, US and Singapore, provides cutting-edge digital technologies that help clinicians provide better care for patients with chronic metabolic diseases, multi-pathologies -organic and cancer. With a strong emphasis on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians through quantitative health assessments enabling early detection, diagnosis and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers and technologists, Perspectum offers a way to manage complex health issues on a large scale.
HepQuant, LLC, headquartered in Denver, Colorado, is a privately held diagnostics company. HepQuant products are experimental drug and in vitro diagnostic device combinations and have not yet been evaluated or reviewed by the United States Food and Drug Administration (FDA) for commercial sale. They are currently available for experimental use through the FDA guidelines for Investigational Device Exemptions (IDEs).
For more information visit www.hepquant.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20211101005151/en/
CONTACT: For Perspectum Nellie Wild
VP Corporate Affairs
[email protected] For HepQuantBradley C. Everson
Director of Business Development
KEYWORD: CALIFORNIA COLORADO UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: GENETIC BIOTECHNOLOGY HEALTH ONCOLOGY
Copyright Business Wire 2021.
PUB: 01/11/2021 08:30 / DISC: 01/11/2021 08:32
Copyright Business Wire 2021.